Radiopharmaceutical Manufacturing Market

Market Outlook

The global radiopharmaceutical manufacturing market, valued at USD 5.86 billion in 2025, is projected to reach USD 6.61 billion in 2026 and USD 13.79 billion by 2035, representing a CAGR of 8.5% during the forecast period from 2026 to 2035.

Market Report: Key Takeaways

Market Size & Trends

• In terms of application area, diagnostic radiopharmaceuticals hold the highest share (around 70%) of the current market.
• With respect to diagnostic radiopharmaceuticals, SPECT radiopharmaceuticals dominate the current market.
• Based on the therapeutic radiopharmaceuticals, gamma emitters capture the largest share (nearly 65%) of the current market; this trend is unlikely to change in the future.
• Amongst the type of radioisotope, Technetium-99m captures most of the current market.
• With respect to the purpose of manufacturing, in-house manufacturers dominate the current market.
• Based on the source of manufacturing, nuclear reactors capture the largest share of the current market; this trend is unlikely to change in the future.
• With respect to the scale of operation, commercial scale dominates (nearly 85%) the current market.
• In terms of the therapeutic area, oncological disorders hold the highest share of the current market.
• In terms of geographical regions, North America currently holds the highest market share (more than 45%).

Market Introduction

Radiopharmaceuticals are specialized drugs that use radioactive isotopes to diagnose and treat various medical conditions, most notably cancer. Over the past few years, radiopharmaceutical developers have extensively used various diagnostic and therapeutic procedures owing to their very short half-life, specificity to targets, and high affinity.

Regulatory agencies have approved over 65 radiopharmaceuticals across the world for the diagnosis and treatment of a myriad of chronic diseases, including infectious diseases, immunological disorders, gastroenteric diseases, cardiovascular disorders, chronic kidney diseases, oncological disorders, neurological disorders, and even certain psychiatric conditions. According to an article published by the World Nuclear Association, more than 10,000 hospitals worldwide claim to use radioisotopes for various diagnostic and therapeutic procedures. Further, it is worth highlighting that healthcare professionals conduct around 40 million diagnostic procedures annually that utilize only one radioisotope, Technetium-99m. Typically, healthcare professionals perform diagnostic tests using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). The introduction of the concept of theranostics, which involves the usage of a single active ingredient for both diagnostic and therapeutic purposes, has opened a new era in patient- centric treatment approach.

The development and production of radiopharmaceuticals are fraught with several challenges, including shortage of production capacity, complex manufacturing processes, lack of skilled labor and stringent guidelines mandated by regulatory agencies. This has prompted drug developers to outsource certain key operations (specifically the complex manufacturing processes) to contract service providers, which further help reduce the cost and expedite the launch of their radioactive drug products in the market. Owing to the increasing research activity and ongoing technological advancements in the field of radiopharmaceuticals, along with the growing burden of chronic diseases, the radiopharmaceutical manufacturing market is likely to witness exponential market growth during the forecast period.

Scope, Methodology and Industry Experts Interviews

The market for radiopharmaceutical manufacturing has a transformative future and is likely to grow at a notable CAGR in the future.

Andreas Fotopoulos (Professor of Nuclear Medicine, University of Ioannina) stated, "The demand for radiopharmaceuticals is going to rise in the near future. This can be primarily attributed to the several newly discovered applications of such products in therapy. In the next few years, we are expecting new therapeutic procedures involving nuclear medicine to hit the market, especially for tumors that are currently considered incurable, such as prostate cancer. Further, there has been a lot of progress in terms of the development of new tracers for both therapy and diagnostic purposes, for use across several disease indications. Therefore, it is safe to expect a substantial growth in the need for nuclear medicines in the coming years."

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

• Head of Business Unit Pharmaceuticals, Mid-sized Company, Austria
• Senior Vice President of Business Development, Mid-sized Company, US
• Former Vice President, Quality / R&D, Small Company, US
• Professor of Nuclear Medicine, Large Company, Greece
• Retired Professor of Medical Imaging / Nuclear Medicine Physician, Very Large Company, Netherlands
• Associate Director and Director, Very Large Company, US
• Anonymous, Large Company, Germany

In addition, the market report includes transcripts of the following other third-party discussions:

• Chief Executive Officer, Small Company, Canada
• Chief Executive Officer, Small Company, Australia
• Chief Executive Officer, Mid-sized Company, US
• Chief Executive Officer, Large Company, Germany
• Chair, Department of Radiology, Large Organization, US
• President, Mid-sized Company, US
• Vice President, Clinical Development, Large Organization, US
• Director and Medical Director, Large Organization, US
• Radiation Oncologist and Co-director, Very Large Organization, US
• Doctor of Medicine, Very Large Organization, US

Market Segmentation

Based on our research, we have segmented the radiopharmaceutical manufacturing market into application area, type of diagnostic radiopharmaceutical, type of therapeutic radiopharmaceutical, type of radioisotope, purpose of manufacturing, source of manufacturing, scale of operation, therapeutic area and geographical regions.

• Application Area: Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
• Type of Diagnostic Radiopharmaceutical: SPECT Radiopharmaceuticals and PET Radiopharmaceuticals
• Type of Therapeutic Radiopharmaceutical: Gamma Emitters, Beta Emitters, and Others
• Type of Radioisotope: Technetium-99m, Lutetium-177, Fluorine-18, and Others
• Purpose of Manufacturing: In-House Manufacturing and Contract Manufacturing
• Source of Manufacturing: Nuclear Reactors, Accelerators / Cyclotrons, and Others
• Scale of Operation: Preclinical Scale, Clinical Scale, and Commercial Scale
• Therapeutic Area: Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Hormonal Disorders, Gastrointestinal Disorders, and Other Disorders
• Geographical Regions: North America (US and Canada), Europe (Germany, France, Spain, Italy, UK, and Rest of Europe), Asia-Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Middle East and North Africa (Israel, South Africa, and Rest of Middle East and North Africa)

Radiopharmaceutical Manufacturing Market Key Insights

What are the Key Drivers for Radiopharmaceutical Manufacturing Market Growth?

• Rising Prevalence of Chronic Disorders: The rising demand for advanced therapeutic modalities for the treatment of various chronic diseases drives the growth of the radiopharmaceutical manufacturing market. It is worth highlighting that researchers are conducting several clinical trials to investigate radiotherapeutics for the treatment of a wide range of diseases across different geographies. This demonstrates the extensive development efforts that stakeholders are undertaking in this domain.
• Increasing Interest Towards Targeted Radiation Therapy: Drug developers have extensively focused on developing targeted radionuclide-based drug therapies in order to overcome the limitations of conventional treatment options. Traditional approaches such as external-beam radiotherapy and systemic chemotherapy often lack tumor specificity, resulting in substantial damage to healthy tissues and dose-limiting toxicities. In contrast, targeted radio-nuclide therapies deliver ionizing radiation selectively to malignant cells via tumor-specific ligands (biologics (peptides, antibodies), or small molecules), enabling higher therapeutic indices while sparing surrounding normal tissue.

What are the Key Radiopharmaceutical Manufacturing Market Trends?

• Partnerships and Collaborations: Several radiopharmaceutical manufacturing companies have recently pursued partnerships to strengthen their market position. Supply agreements emerged as the most prominent partnership model, closely followed by acquisitions. Companies undertake such collaborations to rapidly expand clinical and commercial capabilities, lower development risks, and bypass heavy internal investment. In May 2026, Ratio Therapeutics expanded its manufacturing agreement with PharmaLogic with the aim of supporting clinical development of [Ac-225]RTX-2358.
• Scale-up by Contract Manufacturing Organizations (CMOs): Surging demand for diagnostic and therapeutic radiopharmaceuticals (particularly radioligand therapies using isotopes such as Lutetium-177 and Actinium-225) accelerates the need for radiopharmaceutical contract manufacturers. In April 2026, Nucleus RadioPharma secured USD 50 million financing from OrbiMed to expand manufacturing capacity at its Philadelphia facility with the aim of addressing critical infrastructure needs in precision oncology.

Market Share Insights

Which Application Area Accounts for the Largest Share in the Radiopharmaceutical Manufacturing Market?

• In 2026, diagnostic radiopharmaceuticals hold around 70% of the overall market share, driven by the growing usage of PET and SPECT imaging in early-stage oncology and cardiology, where Technetium-99m remains the primary isotope for diagnostic imaging. In addition, the expansion of diagnostic imaging centers across developing regions and the increasing clinical reliance on molecular imaging provide a predictable, long-term revenue stream with high barriers to entry.
• The therapeutic radiopharmaceuticals segment is likely to grow at a higher CAGR (10.9%) during the forecast period. The theranostics revolution and the success of targeted ligands, such as Lutetium-177 and Actinium-225, which are transforming end-stage cancer treatment, propel this lucrative growth.

Which Type of Radioisotope Accounts for the Largest Share in the Radiopharmaceutical Manufacturing Market?

• According to the radiopharmaceutical manufacturing market forecast, the Technetium-99m segment accounts for around 50% of the overall market revenue. This is due to its favorable physical properties, broad diagnostic applications, and well-established production and distribution infrastructure.
• The Fluorine-18 segment is likely to grow at a higher CAGR (10.2%) during the forecast period.

Regional Analysis: Which Regions are Showing the Fastest Growth in Radiopharmaceutical Manufacturing Industry?

North America Dominates the Market

North America is likely to capture the majority (more than 45%) of the radiopharmaceutical manufacturing market share in 2026, driven by an advanced healthcare ecosystem, high R&D investment, and favorable reimbursement policies that accelerate the adoption of high-priced targeted therapies. In addition, the presence of leading players and a mature regulatory framework (FDA) provide a clear path for commercializing high-margin innovations, such as theranostics ligands.

Asia-Pacific will grow at a relatively faster pace till 2035. Massive infrastructure investments in China and India, including a surge in regional cyclotron facilities and the localization of isotope production to mitigate import reliance, fuel this rapid growth. The convergence of an aging population and government-led nuclear medicine programs create an unprecedented demand for diagnostic and therapeutic capacity in previously underserved urban centers.

Scope of Radiopharmaceutical Manufacturing Market Report

Key Report Attribute	Details
Historical Trend	Since 2023
Forecast Period	Till 2035
Market Size 2026	$ 6.61 Billion
Market Size 2035	$ 13.79 Billion
CAGR (Till 2035)	8.5%
Players	Examples of players covered in the report include BAMF Health, Cardinal Health, DuChemBio, Eckert & Ziegler, Evergreen Theragnostics, Isotopia Molecular Imaging, PharmaLogic, Primo Biotechnology, RadioMedix, SpectronRx (A complete list of players captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

Report Authorship

Author(s): This report was authored by Simriti Gupta, part of Roots Analysis healthcare and pharma research practice, covering technology trends, competitive landscape, and adoption across pharmaceutical and biotechnology companies. All findings are based on proprietary databases, executive interviews, and regulatory analysis, and were subject to internal peer review prior to publication.

Independence and Non-Affiliation

Roots Analysis is an independent secondary and primary market research publisher. This report is not affiliated with, endorsed by, or produced on behalf of any company named or profiled within it, including all key players, and industry expert interviewees referenced above.

Roots Analysis' findings draw on a combination of secondary research and primary interviews with industry experts, of the kind referenced above, to validate market sizing, segment shares, and forecast assumptions independently of any single company's disclosures.

Frequently Asked Questions